VKTX
Viking Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -5.9% ·
share flow -6.2% ·
net new positions -12.5%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 29.61K | $851,871 | n/a | n/a |
| Q2 2026 | 109 | +6 | 57.62M | $2.25B | +10 | −4 |
| Q1 2026 | 106 | -1 | 56.45M | $1.88B | +7 | −8 |
| Q4 2025 | 106 | +1 | 58.95M | $2.07B | +2 | −1 |
| Q3 2025 | 16 | -1 | 41.62M | $1.09B | +2 | −4 |
| Q2 2025 | 15 | 0 | 36.99M | $980.19M | +2 | −2 |
| Q1 2025 | 12 | +3 | 10.64M | $256.98M | +3 | n/a |
| Q4 2024 | 9 | -3 | 10.39M | $418.15M | n/a | −3 |
| Q3 2024 | 11 | -1 | 6.74M | $426.33M | n/a | −1 |
| Q2 2024 | 12 | n/a | 5.57M | $295.04M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 10.00M | -1.6% | $262.78M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | Fidelity (FMR) ✦ | 5.79M | -41.0% | $152.16M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 3 | BlackRock ✦ (passive) | 5.60M | +2.9% | $147.07M | 0.0% | ▲ Add | 2 | SEC ↗ ×18 |
| 4 | JPMorgan Chase ✦ | 5.15M | n/a | $135.45M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 5 | State Street Global Advisors ✦ (passive) | 4.51M | +19.6% | $118.62M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Morgan Stanley ✦ | 3.73M | n/a | $98.00M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 7 | Two Sigma Investments ✦ | 2.09M | +58.7% | $54.81M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 1.90M | +117.5% | $49.89M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Geode Capital Management ✦ (passive) | 1.61M | -16.4% | $42.28M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 427.69K | -54.6% | $11.24M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 11 | Goldman Sachs Group ✦ | 267.74K | n/a | $7.04M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Gotham Asset Management ✦ | 169.68K | New | $4.46M | 0.0% | New | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 161.36K | -21.5% | $4.24M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 123.49K | New | $3.25M | 0.0% | New | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 85.49K | +9.3% | $2.25M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 16 | AQR Capital Management ✦ | 13.07K | -79.8% | $334,386 | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Gotham Asset Management | $4.46M | 0.0% |
| Bridgewater Associates | $3.25M | 0.0% |
Exited
| Norges Bank | $46.85M | was 0.0% |
| Duquesne Family Office | $14.56M | was 0.4% |
| Point72 Asset Management | $1.06M | was 0.0% |
| Renaissance Technologies | $866,550 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 9.80K shares, $318 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.